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Abstract Mucopolysaccharidosis IVA (MPS IVA;Morquio A
syndrome) is an autosomal recessive lysosomal storage disor-
der resulting from a deficiency of N-acetylgalactosamine-6-
sulfate sulfatase (GALNS) activity. Diagnosis can be challeng-
ing and requires agreement of clinical, radiographic, and labo-
ratory findings. A group of biochemical genetics laboratory
directors and clinicians involved in the diagnosis of MPS
IVA, convened by BioMarin Pharmaceutical Inc., met to de-
velop recommendations for diagnosis. The following conclu-
sions were reached. Due to the wide variation and subtleties of
radiographic findings, imaging of multiple body regions is
recommended. Urinary glycosaminoglycan analysis is particu-
larly problematic for MPS IVA and it is strongly recommended
to proceed to enzyme activity testing even if urine appears
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normal when there is clinical suspicion of MPS IVA. Enzyme
activity testing of GALNS is essential in diagnosing MPS IVA.
Additional analyses to confirm sample integrity and rule out
MPS IVB, multiple sulfatase deficiency, and mucolipidoses
types II/III are critical as part of enzyme activity testing.
Leukocytes or cultured dermal fibroblasts are strongly recom-
mended for enzyme activity testing to confirm screening
results. Molecular testing may also be used to confirm the
diagnosis in many patients. However, two known or probable
causative mutations may not be identified in all cases of MPS
IVA.A diagnostic testing algorithm is presentedwhich attempts
to streamline this complex testing process.
Introduction
Mucopolysaccharidosis IVA (MPS IVA; OMIM #253000),
also known as Morquio A syndrome, is an autosomal recessive
lysosomal storage disorder resulting frommutations in the gene
encoding N-acetylgalactosamine-6-sulfate sulfatase (GALNS;
EC 3.1.6.4) (Tomatsu et al 2005a). GALNS is required for the
degradation of two glycosaminoglycans (GAGs), chondroitin-
6-sulfate (C6S) (Matalon et al 1974; Singh et al 1976) and
keratan sulfate (KS) (Glossl and Kresse 1982; Yutaka et al
1982). Defects in GALNS can lead to disturbance of lysosomal
breakdown of KS and C6S with subsequent storage within the
lysosomes and disruption of cell function and metabolism
causing tissue and organ dysfunction. Some of the excess
GAGs may also be excreted in urine with abnormal KS excre-
tion often occurring in MPS IVA and B. MPS IVB (OMIM
#253010), although phenotypically similar to MPS IVA, is a
separate disorder and is caused bymutations in a different gene,
the GLB1 gene which encodes β-galactosidase (EC 3.2.1.23).
As in all mucopolysaccharidosis (MPS) disorders, the tissue
distribution pattern of the specific GAGs accumulated deter-
mines the clinical manifestations of the disorder. In MPS IVA
these manifestations can include short stature, skeletal abnor-
malities, cervical instability, limited endurance, visual and
auditory impairment, oral health challenges, cardiovascular
abnormalities, and significant respiratory system compromise
(Montano et al 2007; Hendriksz et al 2012). The accumulation
of KS in cartilage, as opposed to bone, is responsible for the
skeletal manifestations characteristic of MPS IVA (and B)
(Hollister et al 1975). Developmental delay, seizures, and other
serious CNS involvement are not typically a component of
MPS IVA (McKusick and Neufeld 1983). There is a wide
spectrum of phenotypic presentations (Beck et al 1986). Se-
verely affected patients typically do not survive beyond the
second or third decade of life while patients with the attenuated
form of the disease may survive for over 70 years (Tomatsu et
al 2011). An international MPS IVA registry found that 64 %
of patients registered were below 18 years of age (Montano et
al 2007). The heterogeneity of the mutations in the GALNS
gene (Tomatsu et al 2005a) is likely responsible for the variable
phenotypic presentation; however, additional genetic, environ-
mental, and metabolic factors may also play a role.
This variability of phenotypic presentation can delay the
diagnosis by years or even decades (Tylki-Szymanska et al
1998; Gosele et al 2000). Several caveats in MPS IVA diag-
nostic testing can further complicate and delay the diagnostic
process. The combination of clinical and laboratory diagnostic
challenges make MPS IVA particularly prone to both delayed
diagnoses and misdiagnoses. Unfortunately, the time between
onset of initial symptoms and diagnosis is typically on the
order of years (Holzgreve et al 1981; Montano et al 2007).
However, due to the progressive and often life-threatening
nature of the disease (Montano et al 2007), early and accurate
diagnosis is critical for optimal patient management. Clinicians
and laboratories should both be aware of the possible compli-
cations of diagnostic testing forMPS IVA and work together to
ensure that an accurate diagnosis is reached in a timely manner.
With the goal of illuminating the MPS IVA diagnostic
process, a group of biochemical genetics laboratory directors
and clinicians involved in the diagnosis of MPS IVA partici-
pated in surveys and met in working groups to develop rec-
ommendations for an MPS IVA diagnostic algorithm. The
working groups met in Prague on June 16–18, 2011 and in
San Diego on February 6–7, 2012. BioMarin Pharmaceutical
Inc. administered the surveys and organized the meetings. A
diagnostic algorithm was developed (Fig. 1). Additional back-
ground information was compiled and recommendations re-
garding key diagnostic elements were established in support
of the algorithm.
Establishing clinical suspicion
The path to diagnosis begins with the development of clinical
suspicion of MPS IVA (Table 1). Clinical suspicion can orig-
inate from clinical findings, radiographic findings, or a com-
bination of both. Patients typically appear normal at birth then
begin to develop symptoms at varying rates depending upon
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the severity of their disease (Montano et al 2007). Severely
affected patients will usually present with signs and symptoms
within the first year of life while patients with attenuated
disease may not develop initial symptoms until later in child-
hood or adolescence (Montano et al 2007). Initial signs and
symptoms vary from patient to patient and may be present
alone or in combination (Montano et al 2007). The presence or
absence of any particular sign or symptom does not rule out or
confirm MPS IVA. Many patients are initially seen by special-
ists such as orthopedic surgeons, ophthalmologists, or rheuma-
tologists who may not be familiar with MPS IVA (Aldenhoven
et al 2009; Lehman et al 2011; Summers and Ashworth 2011).
Increased awareness of MPS disorder signs and symptoms,
especially those which do not fit the classic phenotype, among
these specialists is needed to facilitate prompt referral to a
physician familiar with the diagnosis of inherited metabolic
disorders such as a clinical geneticist or a metabolic specialist.
Common patient-reported initial skeletal symptoms include
short stature, abnormal gait, genu valgum, pectus carinatum (or,
more rarely, pectus excavatum), and spinal abnormalities
(Montano et al 2007). Spinal abnormalities include odontoid
hypoplasia, cervical instability, kyphosis/gibbus, and scoliosis
(Tomatsu et al 2011). Gibbus in particular is often the first sign
noticed in MPS IVA (Northover et al 1996). However, in
patients with attenuated disease, hip stiffness and pain are more
likely to be the initial signs reported (Wraith 1995). Diagnosis
tends to be very challenging in these cases because they do not
exhibit the classical signs of the disease. Patients with attenu-
ated MPS IVA may undergo extensive medical treatment, such
as corrective orthopedic surgeries, to address their symptoms
prior to being identified as MPS IVA cases (Prat et al 2008).
This can pose a significant risk for the patient as MPS IVA is
often attended with anesthetic and perioperative compli-
cations (Theroux et al 2012) which may not be antici-
pated in the absence of an MPS IVA diagnosis.
Regardless of severity, as the disease progresses, more signs
and symptoms appear. Joint hypermobility (of the wrist in
particular) may develop and can be especially helpful in estab-
lishing clinical suspicion as it is unique to MPS IVA (Tomatsu
et al 2011) and MPS IVB (Gucev et al 2008) among the MPS
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disorders. In fact, joint hypermobility is quite rare among all of
the lysosomal storage diseases which generally tend to cause
joint stiffness (Aldenhoven et al 2009). Aspartylglucosaminu-
ria (OMIM #208400) is an exception to this generalization
(Isenberg and Sharp 1975; Beaudet 1983). The absence of
intellectual disability is also helpful in differentiating MPS
IVA from several other lysosomal storage diseases.
Although MPS IVA has historically been considered a skel-
etal disease, the significance of the non-skeletal features has
recently been described (Hendriksz et al 2012). Non-skeletal
abnormalities may also provide key insight into the clinical
diagnosis of MPS IVA. Signs of respiratory compromise, such
as limited endurance, frequent respiratory tract infections, sleep
apnea, and snoring, are common in MPS IVA (Hendriksz et al
2012). Other non-skeletal findings include mitral and/or aortic
value regurgitation and thickening, conductive and sensorineu-
ral hearing loss, and muscle weakness (Hendriksz et al 2012).
Visual impairment inMPS IVA differs slightly from otherMPS
disorders. Corneal clouding, although common, is milder,
astigmatism can occur, and reported cases of glaucoma have
been open-angle as opposed to closed-angle as reported for
other MPS disorders (Hendriksz et al 2012). Dental ab-
normalities, including spaced dentition, pointed cusps,
spade-shaped incisors, and enamel hypoplasia are also char-
acteristic of MPS IVA (Levin et al 1975; Nelson et al 1988;
Hendriksz et al 2012). Due to both dental and upper extremity
abnormalities, maintaining oral health can be particularly
challenging (James et al 2012).
A patient’s surgical history can be another element used to
establish clinical suspicion. Adenoidectomy, tonsillectomy,
hernia repair, and ear ventilation tubes can all be suggestive
of an MPS disorder while cervical decompression and/or
fusion and limb alignment surgeries at a young age
are common in MPS IVA in particular (Tomatsu et al 2011).
When MPS IVA is suspected, radiographic imaging should
be performed as a component of the diagnostic process. Due to
the wide variation and subtleties of radiographic findings in
MPS IVA, it is recommended to obtain a skeletal survey to
allow evaluation of multiple parts of the body, including skull,
complete spine (including lateral views), hips, and limbs (par-
ticularly hands and wrists). Radiographic findings in MPS IVA
(Fig. 2) can include odontoid hypoplasia, atlantoaxial subluxa-
tion, thickened skull, J- or omega-shaped sella turcica, flared
ribs, short thorax with wide anterior posterior diameter, con-
stricted iliac wings, underdeveloped acetabula, flattened capital
femoral epiphyses, coxa valga, universal platyspondyly, ante-
rior beaking of the vertebrae, short ulna, and delayed bone age
or dysplastic carpal/tarsal and metacarpal/metatarsal bones.
Although classified by the International Working Group
on Constitutional Diseases of Bone as part of the dysostosis
multiplex group (Spranger 1992), MPS IVA can appear
similar to several other skeletal dysplasias not classified as
part of that group (Table 2). While a comprehensive review
of these disorders is beyond the scope of this article, a few
key differential diagnoses are described in detail to highlight
specific diagnostic challenges. Since MPS IVA can be
conclusively confirmed or ruled out using laboratory
testing and many other skeletal disorders are diagnosed
based on clinical evidence alone, performing laboratory
tests for MPS IVA whenever it is considered a possible
differential diagnosis is recommended.
Radiographically, skeletal changes in MPS IVA can ap-
pear very similar to those seen in the osteochondrodyspla-
sias classified by the International Working Group on
Constitutional Diseases of Bone (Spranger 1992) as spon-
dyloepiphyseal dysplasias (SEDs). Congenital SEDs can
usually be differentiated from MPS IVA because symptoms
are present at birth. However, there are also several forms of
SED in which affected individuals may appear normal at
birth, making differentiation from MPS IVA more difficult.
Two SEDs, Dyggve-Melchior-Clausen syndrome (DMC;
OMIM #223800) and SED, Maroteaux type (OMIM
#184095), were previously known as pseudo-Morquio syn-
drome types 1 and 2, respectively, due to their skeletal
resemblance to MPS IVA (Nishimura et al 2010).
DMC, originally reported as Morquio-Ullrich’s disease
(Dyggve et al 1962), is caused by mutations in the DYM
gene (El Ghouzzi et al 2003) and can be clinically differen-
tiated from MPS IVA because patients are intellectually
disabled. However, mutations in the same gene can also
cause Smith-McCort syndrome (SMC; OMIM #607326), a
condition radiographically identical to DMC in which intel-
ligence and psychomotor development are normal (Cohn et
al 2003). In radiographs, both DMC and SMC appear similar
Table 1 Signs and symptoms that should generate clinical suspicion
of MPS IVA
Skeletal abnormalities Non-skeletal abnormalities
Short stature Respiratory compromisea
Abnormal gait Endurance limitations
Genu valgum Recurrent respiratory infections
Spinal abnormalities Sleep apnea
Odontoid hypoplasia Snoring
Cervical instability Cardiac valve abnormalities
Kyphosis/Gibbus Muscular weakness
Scoliosis Visual impairment
Chest abnormalities Corneal clouding
Pectus carinatum Astigmatism
Pectus excavatum Hearing lossa
Joint abnormalities Conductive
Joint hypermobility Sensorineural
Joint pain Dental abnormalities and
oral health challengesa
a These abnormalities may be manifestations of underlying skeletal
abnormalities
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to MPS IVA, including the presence of atlantoaxial instability
caused by odontoid hypoplasia, but can be differentiated by a
characteristic lace-like appearance of the iliac crests
(Nakamura et al 1997) which is absent in MPS IVA.
SED, Maroteaux type is part of a family of skeletal dys-
plasias caused by dominant mutations in the TRPV4 gene
(Nishimura et al 2010). SED, Maroteaux type can be differ-
entiated from MPS IVA clinically by the absence of the
previously discussed non-skeletal features; however, radio-
graphically, the conditions are very similar (Doman et al
1990). Radiographic differences are seen mainly in the spine
and the hip (Doman et al 1990; Megarbane et al 2004). In
MPS IVA, platyspondyly is irregular, anterior beaking often
develops on the vertebrae, and there is coxa valga with
flattened epiphyses as opposed to SED, Maroteaux type in
which the platyspondyly is smooth and uniform, anterior
beaking of the vertebrae is not present, and the upper femoral
metaphyses are enlarged and short (Doman et al 1990;
Megarbane et al 2004). SED, Maroteaux type may also
be referred to as spondyloepimetaphyseal dysplasia
(SEMD) of Maroteaux (Megarbane et al 2004).
A third SED, X-linked SED tarda (X-linked SED; OMIM
#313400), although distinct from classical MPS IVA, can ap-
pear very similar to mild cases of MPS IVA, but can be differ-
entiated by coxa vara, disproportionately long arms relative to
height, and characteristic superior and inferior humping of
vertebral bodies (Whyte et al 1999) which are not seen in
MPS IVA. An autosomal recessive variant of SED has also
been identified, however, unlike MPS IVA, intellectual disabil-
ity is a feature (Kohn et al 1987a). Additional differential
diagnoses include spondylometaphyseal dysplasia, Kozlowski
type (SMDK; OMIM #184252) and brachyolmia (OMIM
#271530, 271630, 613678, 113500). Individuals with SMDK
have platyspondyly, overfaced vertebral pedicles, irregular
proximal femoral growth plates, and carpal ossification delay
(Krakow et al 2009). Brachyolmias are a heterogeneous group
Fig. 2 Example radiographic
findings specific for MPS IVA.
a anterior beaking of the
vertebrae; b short ulna and
delayed bone age or dysplastic
metacarpals; c constricted iliac
wings, underdeveloped
acetabula, and flattened capital
femoral epiphyses
Table 2 Select non-dysostosis multiplex skeletal disorders which may be confused with MPS IVA
Category Differential diagnosis Distinguishing clinical/radiographic features References
Spondyloepiphyseal
dysplasia (SED)
SED congenita Symptoms present from birth (Fraser et al 1969)
Dyggve-Melchior-Clausen
syndrome (pseudo-Morquio
syndrome type 1)
Intellectual disability and lace-like appearance of the
iliac crests in radiographs
(Nakamura et al 1997;
Nishimura et al 2010)
Smith-McCort syndrome Lace-like appearance of the iliac crests in radiographs (Nakamura et al 1997; Cohn
et al 2003; Nishimura et al
2010)
SED, Maroteaux type (pseudo-
Morquio syndrome type 2)
Smooth and uniform platyspondylysis, no anterior
beaking of the vertebrae, upper femoral metaphyses
are enlarged and short
(Doman et al 1990;
Megarbane et al 2004;
Nishimura et al 2010)
X-linked SED tarda Coxa vara, disproportionately long arms relative to
height, superior and inferior humping of vertebral
bodies
(Whyte et al 1999)
Autosomal recessive SED tarda Intellectual disability (Kohn et al 1987b)
Spondylometaphyseal
dysplasia (SMD)
SMD, Kozlowski type Overfaced vertebral pedicles, irregular proximal
femoral growth plates
(Krakow et al 2009)
Brachyolmia Types 1, 2, and 3 Lack of long bone involvement (Shohat et al 1989)
Other Legg-Calve-Perthes disease Involvement limited to hips (Miyamoto et al 2007)
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of skeletal dysplasias characterized radiographically by gener-
alized platyspondyly without significant long bone abnormali-
ties (Shohat et al 1989).
If a mild case of MPS IVA presents with hip pain alone
and additional areas of the skeleton are not imaged, it is also
possible to misdiagnose the patient as having Legg-Calve-
Perthes disease (OMIM #120140), a form of avascular ne-
crosis of the femoral head (Miyamoto et al 2007). At least
one such case in which an MPS IVA patient was initially
diagnosed with bilateral Legg-Calve-Perthes disease has
occurred recently (manuscript under development).
Although clinical findings and radiographs can provide
substantial insight, laboratory testing is required to reach a
diagnosis of MPS IVA. It is also important to note that when
an alternative skeletal dysplasia is suspected but MPS IVA is
considered enough of a possibility that the clinician chooses
to perform a laboratory test to rule out the MPS disorders,
urinary screening is not an acceptable method to use alone
due to high false negative rates for MPS IVA. This issue is
discussed in detail in the urinary screening section.
Laboratory testing
Once clinical suspicion of MPS IVA has been established,
laboratory testing can be used to reach a diagnosis. A variety
of laboratory testing methods are currently available. Screen-
ing can be performed either by testing for abnormal elevation
of urinary GAG levels and presence of excess KS or by
measuring enzyme activity from a dried blood spot (DBS).
Each screening method has advantages and disadvantages
which will be discussed in detail. The screening method
selected often depends upon the availability of testing and of
samples. Alternatively, if suspicion of MPS IVA is strong,
clinicians may elect to bypass screening assays. A compre-
hensive list of all testing laboratories is beyond the scope of
this article, however, readers are directed to websites such as
GeneTests (www.GeneTests.org) or the genetic test registry
(GTR) (www.ncbi.nlm.nih.gov/gtr/) for a list of laboratories
offering diagnostic testing.
Throughout the diagnostic process, maintaining open
communication between the clinician and laboratory per-
sonnel facilitates efficiency and helps reduce errors. Infor-
mation regarding the clinical suspicion of MPS IVA allows
the laboratory to ensure that the most appropriate tests are
performed and aids in the interpretation of results. Clear
communication of the results to the clinician ensures that
the results are acted on appropriately.
As diagnostic testing for this disorder is difficult, the
laboratory process can be enhanced by participation in ex-
ternal proficiency testing programs. These programs can
improve consistency by allowing laboratories to monitor
their competency for a particular test over time and relative
to other laboratories. Proficiency testing is currently offered
for MPS urinary analysis and/or enzyme activity testing by
the College of American Pathologists (CAP) and the
European Research Network for Evaluation and Improvement
of Screening, Diagnosis and Treatment of Inherited Disorders
of Metabolism (ERNDIM).
A significant challenge for these programs, however, is
the lack of sufficient amounts of positive patient samples.
Clinicians, laboratories and proficiency testing programs are
encouraged to work together to overcome this challenge.
Urinary screening
Adequate sample quality is essential for urinary screening.
Dilute urine samples can be particularly problematic and
may not be accepted by the laboratory. A first morning void
or 24 h collection is preferred and a minimum of 15 mL of
sample is usually recommended; however, patient age must
be taken into consideration. As shipping, handling, and
logistical considerations for urine samples vary, clinicians
should contact the laboratory for specific details.
Urinary screening is based on the excretion of excess
GAGs that occurs in the MPS disorders. The urinary excre-
tion of GAGs, when normalized to creatinine, is high in
infants and young children, decreases with age, plateaus in
the second decade of life, and remains constant through
adulthood (de Jong et al 1989; Whitley et al 1989a; Piraud
et al 1993; Gray et al 2007; Wood et al 2012). Evaluations
can be done for both the total amount of GAG excreted
(quantitative analysis) and the specific types of GAG
excreted (qualitative analysis). In the case of MPS IVA,
evaluating both simultaneously is critical to avoid false
negative results as KS can be present without elevating the
total amount of GAG above the upper limits for unaffected
individuals (Whitley et al 1989a; Piraud et al 1993; Tomatsu et
al 2004; Gray et al 2007). Determining both total urinary
GAG quantity and GAG identity is strongly recommended,
especially if MPS IVA is considered a possibility.
Some of the methods for analyzing total urinary GAG
used in the past, such as spot tests and turbidity tests, are no
longer recommended. Spot tests for MPS have very poor
specificity (12–29 % false positives) and sensitivity (19–
35 % false negatives) and do not allow for interpretation of
results by patient age or sample concentration (Pennock
1976; de Jong et al 1991). The cetylpyridinium chloride
(CPC) assay, a turbidity test based on GAG precipitation,
also has a high false negative rate reported to range from 11
to 30 % depending upon the pH, with MPS IVA being the
most commonly missed MPS (de Jong et al 1989). Another
test for total urinary GAG, the uronic acid-carbazole test is
particularly unsuited for use when MPS IVA or B is sus-
pected because it is based on the measurement of uronic acid
in GAGs; however, KS, the main GAG excreted in MPS
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IVA and B, does not contain uronic acid residues. Therefore,
MPS IVA and B cannot be reliably detected by the uronic
acid-carbazole test (de Jong et al 1989; Frazier et al 2008).
Currently, the analysis of total urinary GAG is usually
performed in a quantitative manner by spectrophotometric
analysis of urine combined with a cationic blue dye such as
dimethylmethylene blue (DMB) (Whitley et al 1989b). Total
GAG is reported relative to creatinine to normalize for urinary
concentration and age-based reference ranges are used to
interpret results (de Jong et al 1989). As previously discussed,
although most MPS IVA patients do excrete KS, many do not
excrete enough to elevate their total urinary GAG level above
the reference range for unaffected individuals. This results in
an unacceptably high false negative rate when this quantitative
analysis is performed alone, 15 % for MPS in general and
higher for MPS IVA in particular (Whitley et al 1989a;
Tomatsu et al 2004; Gray et al 2007). To reduce false
negative rates, running a qualitative analysis simultaneously
is strongly recommended (Piraud et al 1993; Gray et al 2007).
Qualitative analyses isolate GAGs from urine then separate
them using either thin layer chromatography or electrophore-
sis (Wessler 1968; Humbel and Chamoles 1972). GAG iden-
tity is determined by relative position on the plate or gel.
While the results are not quantitative, they can provide sub-
stantial insight into which MPS disorder is present and may
reveal the presence of KS for some patients whose total
urinary GAG levels are not elevated (Piraud et al 1993).
Unfortunately, KS can be challenging to separate and visual-
ize. Separation can be improved by using either multiple-step
1D electrophoresis (Hopwood and Harrison 1982) (Fig. 3) or
2D electrophoresis (Hata and Nagai 1972) (Fig. 4). However,
despite the improved separation, interpretation of results is
still subjective and can be challenging (Fig. 5).
Tandem mass spectrometry detection (MS-MS) and
quantification of several GAG species or KS alone is an
attractive alternative to the methods previously described
(Oguma et al 2007; Ohashi et al 2009; Tomatsu et al 2010;
Hintze et al 2011). A new method for quantifying urinary
KS alone, as opposed to total urinary GAG, has recently
been described (Martell et al 2011) and is based on the
method that has been previously published (Oguma et al
2007). Keratanase II is used to digest KS and the resulting
disaccharides are analyzed by LC-MS/MS. While currently
used (non MS-MS) methods of urinary GAG analysis are
either qualitatively specific for KS but non-quantitative or
non-specific for KS and only quantitative for total GAG,
this new method has the advantage of being both KS-
specific and quantitative. Additionally, the LC-MS/MS
method is likely to provide higher sensitivity than other
methods. Reported assay validation results show separation
between MPS IVA patient (n=160) and unaffected control
(n=186) KS ranges in urine and provide compelling evidence
for the clinical utility of this method. However, the degree of
separation is small, particularly for older patients (0.2–1.3
(unaffected) vs. 1.7–37.9 (affected) μg/mg creatinine for
patients >15 years of age) (Martell et al 2011). The increased
sensitivity and specificity of this technology has provided
renewed interest in the analysis of KS in blood. While some
research suggests that blood KS may be an additional bio-
marker of interest in MPSIVA patients, further research is
needed to understand its use and determine the best methods
for analysis (Oguma et al 2007; Martell et al 2011; Hintze et al
2011). Finally, another new method has been described for
analysis of non-reducing ends of urinary GAGs by LC-MS.
Currently this method does not provide a measure of non-
reducing ends for MPS IVA (Lawrence et al 2012). MS/MS
methodology for the analysis of KS is not widely available in
diagnostic, clinical settings which limit its current usefulness
to physicians. However, with increased interest in MS-MS
assays and the wider availability of the required reagents, MS-
MS methodologies are likely to have a large impact in the
diagnosis of and monitoring of MPS IVA in the future.
Ultimately, while both quantitative and qualitative uri-
nary GAG analyses can provide insight into the diagnosis,
they are still considered screening methods and can produce
false positive and false negative results (Piraud et al 1993).
The relatively high rate of false negatives is particularly
problematic in mild cases where a clinician may not suspect
MPS IVA and is interested in using urinary analysis to rule
out the diagnosis. It is this testing strategy in patients with
borderline or normal total urinary GAGs and/or KS that
often leads to the diagnosis being missed or delayed. While
most MPS IVA patients excrete KS (Tomatsu et al 2004;
Martell et al 2011), the absence of KS excretion in MPS IVA
has been reported in the past (Fujimoto and Horwitz 1983).
This may have been due to the limited sensitivity of the
technology available at the time. However, regardless of the
technology used, urine analysis is likely to be more chal-
lenging in older patients especially those with the mild form
1 2 3 4
CS
KS
Fig. 3 Multiple-step 1D electrophoresis qualitative urinary GAG anal-
ysis (Hopwood and Harrison 1982). KS keratan sulfate, CS chondroitin
sulfate, lane 1: MPS I/II control, lane 2: MPS IVA patient, lane 3:
unaffected control, lane 4: MPS IVA positive control
J Inherit Metab Dis (2013) 36:293–307 299
of the disease who do not present with symptoms until
adolescence. One of the main sources of KS is cartilage,
so as bone growth centers close in patients reaching puberty,
the rate of KS accumulation slows and urinary excretion is
substantially reduced and may even disappear (Longdon and
Pennock 1979). Therefore, false negative results become
more likely as patients age. Increased disease awareness
may also lead to increased false negative rates as milder
cases with lower KS levels are screened more often. Whether
or not the new LC-MS/MS method will be able to overcome
these challenges remains to be seen. Regarding the specificity
of urinary analysis for MPS IVA, patients with MPS IVB and
multiple sulfatase deficiency (OMIM # 272200) also excrete
KS (Arbisser et al 1977; Groebe et al 1980) and, although
unexpected, elevated KS has been reported in other MPS
disorders and mucolipidoses (Tomatsu et al 2005b). KS can
also be elevated in other lysosomal disorders such as Fucosi-
dosis (OMIM # 230000) and GM1 gangliosidosis (OMIM
#230500, 230600, 230650) which is caused by the same
enzyme deficiency as MPS IVB (Ullrich and Kresse 1996).
Hence the absence of KS does not conclusively rule out MPS
IVA and the presence of KS does not conclusively diagnose
MPS IVA. Proceeding to enzyme activity analysis even if
urinary analysis results are negative is strongly recommended
if there is clinical suspicion of MPS IVA.
In addition to being used to screen for MPS, urinary
analysis is also commonly used in other MPS disorders to
track a patient’s response to enzyme replacement therapy
(ERT) (Wraith et al 2004; Harmatz et al 2006; Muenzer et al
2006). Should ERT become available for MPS IVA, using
urinary analysis to track MPS IVA patient responses may
present a significant challenge. New methodology, such as
the LC-MS/MS assay, or possibly even new biomarkers,
may be required to successfully quantify biochemical
patient outcomes.
Enzyme activity analysis
Diagnosis of MPS IVA requires the demonstration of a
deficiency in GALNS activity. Fibroblasts and leukocytes
are the recommended sample types for this analysis. Prenatal
samples, such as dissected chorionic villi, cultured chorionic
villus cells, and amniocytes, can also be used, facilitating
prenatal diagnosis (Zhao et al 1990; Kleijer et al 2000).
Additionally, protocols for evaluating GALNS activity in a
DBS have recently been proposed as screening methods
(Duffey et al 2010; Camelier et al 2011).
Fibroblast samples are recommended for enzyme activity
analysis because the impact of environmental and logistical
factors during shipment can be minimized and corrected
through culturing of the cells in the receiving laboratory. The
culturing process also allows for the generation of a large
number of cells for analysis and more cells can be grown at
a later time if further analyses are needed. On the other hand,
skin punch biopsies are invasive and a significant amount of
time is required prior to analysis to culture the cells (ranging
from 2 to 10 weeks) which can occasionally fail to grow or
become contaminated. The total time from sample collection
CS
KS
CS CS
KS KS
Fig. 4 Positive 2D
electrophoresis qualitative
urinary GAG analysis results
for MPS IVA. KS keratan
sulfate, CS chondroitin sulfate
Fig. 5 Challenging to interpret urinary GAG 2D electrophoresis results from MPS IVA patients illustrating the difficulty in discerning the presence of
keratan sulfate. All patients were subsequently confirmed to have MPS IVA by enzyme activity analysis
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to the reporting of results to the clinician can be relatively
lengthy, particularly if problems are encountered during cell
culture and the culturing process has to be repeated. Some
laboratories also require that the fibroblasts from the skin
punch biopsy are cultured prior to being sent to the laboratory
which requires considerable time, effort, and expertise on the
part of the establishment sending the sample.
Leukocytes isolated fromwhole blood allow for more rapid
analysis as cell culture is not required. Typically, the time from
sample collection to the reporting of results to the clinician is
less than 2 weeks. Whole blood samples normally provide a
sufficient number of cells for analysis; however, additional
cells cannot be generated by cell culture, so another sample
must be obtained if the initial sample is insufficient or if the
results are inconclusive. Furthermore, leukocyte samples are
susceptible to environmental extremes during shipping in
countries with a hot climate (Burin et al 2000). Sample dete-
rioration may also become an issue when shipping long dis-
tances results in a prolonged amount of time spent in transit.
This has lead many laboratories to require arrival of the
sample within 24 to 48 h post-draw. Ultimately, the measure-
ment of lysosomal enzymes in blood requires careful attention
to the quality of the incoming sample including measurement
of controls to verify sample integrity.
DBS samples are a convenient sample type both in
regions where it is difficult to ship whole blood or tissue
samples and for newborn screening programs. However, as
described for leukocytes, proper sample collection and ship-
ping are critical to the success of the analysis (Camelier et al
2011). A video on DBS collection technique is available
online (Fundación para el Estudio de las Enfermedades
Neurometabólicas 2011). The date of collection should al-
ways be noted on the card to aid in interpretation of results.
The card should be dried at room temperature for at least
4 h. Due to the temperature sensitive nature of GALNS in a
DBS (Camelier et al 2011), cards should be stored at 4°C
after drying and shipped promptly; the longer the period of
time between collection and analysis, the higher the risk of a
false positive result. If high temperatures are possible during
shipment, the card should be shipped in an insulated con-
tainer with ice packs (Camelier et al 2011).
While measurement of GALNS activity in DBS samples
is very useful for screening, this method is not as robust as it
is in fibroblasts or leukocytes due to the lower number of
cells present in the sample. Furthermore, more data are
needed to evaluate GALNS stability in a DBS, especially
since DBS samples are more likely to be exposed to envi-
ronmental extremes during shipping than leukocytes. For
these reasons, DBS results should not be used alone to reach
a diagnosis. Confirming positive DBS results by enzyme
activity analysis in fibroblasts or leukocytes is strongly
recommended. Alternatives are discussed in the section
entitled “Reaching a diagnosis”.
It is important to note that if a patient has recently
received a blood transfusion or a bone marrow/stem cell
transplant, enzyme activity analysis in both leukocyte and
DBS samples could give inaccurate results. If there is any
concern for this type of interference, consultation with the
laboratory is recommended or, at minimum, this information
should be included on the sample requisition. Fibroblast
samples will not be impacted by these treatments and are
recommended in these instances.
GALNS acts on two substrates, N-acetylgalactosamine-6-
sulfate (GalNAc-6S) (Matalon et al 1974) and galactose-6-
sulfate (Gal-6S) (Glossl and Kresse 1982; Yutaka et al 1982).
GalNAc-6S is a component of C6S and Gal-6S is a compo-
nent of KS. Both of these substrates are used currently to
demonstrate deficient GALNS activity. TheGalNAc-6S based
assay uses radio-labeled natural substrate (Glossl and Kresse
1978) and the Gal-6S based assay uses fluorogenic artificial
substrate (van Diggelen et al 1990). The radio-labeled sub-
strate, a tritiated disulfated trisaccharide prepared from C6S,
was developed first (Glossl and Kresse 1978). Using this
substrate, GALNS activity is determined based on the amount
of radioactivity released from the substrate with a lack of
GALNS activity resulting in low generation of signal. Al-
though this method is still in use, many laboratories have
opted to switch to an assay based on a fluorogenic substrate
(van Diggelen et al 1990). The fluorogenic assay uses 4-
methylumbelliferyl-β-D-galactopyranoside-6-sulfate (4MU-
Gal6S) as the substrate and is accomplished in two steps.
First, GALNS present in the sample removes the 6-sulfate,
and then exogenous β-galactosidase removes the galactoside,
freeing the 4-methylumbelliferone adduct, which fluoresces
under high pH. The addition of exogenous β-galactosidase to
the reaction mixture is critical because conditions in which β-
galactosidase is deficient (MPS IVB, I-cell disease (OMIM
#252500), and GM1 gangliosidosis) would result in signifi-
cant GALNS activity underestimation and possibly misdiag-
noses (van Diggelen et al 1990). Removal of endogenous
phosphates and sulfates is also important as they are lysosom-
al sulfatase inhibitors (van Diggelen et al 1990). Modification
of the original published protocol (van Diggelen et al 1990) by
increasing the substrate concentration ten-fold is recommen-
ded to increase assay sensitivity.
In addition to these two currently used methods, a
tandem mass spectrometry based method using a novel
substrate has recently been developed (Duffey et al
2010). Incorporation of this new assay into a multi-
plexed lysosomal storage disease panel for use in new-
born screening programs is being considered (Khaliq et
al 2011).
Regardless of the methods used, performing enzyme
activity analysis for MPS IVA should also involve the eval-
uation of additional enzymes to control for sample integrity
and to rule out differential diagnoses.
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To confirm that low GALNS activity is not due to sample
degradation, the activity of a reference enzyme with similar
stability in the same sample should be measured. If a DBS is
used, measuring a reference enzyme in the same sample to
confirm integrity is still recommended, but may not be
sufficient to rule out an effect of handling on GALNS
activity because the stability of GALNS as compared to
other enzymes in a DBS is not known. Simultaneously
collecting and shipping a negative control DBS sample
(from an unaffected healthy individual) to confirm sample
handling has not compromised GALNS activity is recom-
mended (Camelier et al 2011). However, obtaining control
samples may be difficult logistically for some laboratories,
particularly for routine testing of a large number of patients.
Parental or familial samples are not recommended for this
purpose as their GALNS activity level may be below normal
if they are carriers.
It is also important to confirm that the low GALNS
activity is not being caused by a different disease. Multiple
sulfatase deficiency (MSD) and mucolipidosis II or III (ML
II/III) also impact GALNS activity. MSD is a disease in
which the activities of several sulfatases, including GALNS,
are deficient (Dierks et al 2003) and ML II/III impair
mannose-6-phosphate guided enzyme targeting causing ly-
sosomal enzyme activities to be low in fibroblasts, elevated
in plasma, and relatively unaltered in leukocytes (Neufeld
and McKusick 1983). Both diseases can be alternative
causes of low GALNS activity depending on the sample
type used. The possibility of MSD should be evaluated by
measuring the activity of a second sulfatase such as arylsul-
fatase B (EC 3.1.6.12) or iduronate-2-sulfatase (EC
3.1.6.13). If a leukocyte sample or a DBS was used for
GALNS analysis, ML II/III is not a concern as GALNS
activity is not decreased by ML II/III in this specific
sample type. However, if fibroblasts were used, ML II/III
must be ruled out. This can be accomplished by measuring a
second mannose-6-phosphate targeted enzyme such as
β-galactosidase, arylsulfatase B, iduronate-2-sulfatase,
β-hexosaminidase (EC 3.2.1.52), or α-iduronidase (EC
3.2.1.76) in fibroblasts.
Lastly, ruling out MPS IVB during enzyme analysis is also
highly recommended. MPS IVA and B can present with very
similar symptoms and can both cause elevated urinary KS
(McKusick and Neufeld 1983). Therefore, β-galactosidase,
the enzyme deficient in MPS IVB, is commonly tested in
conjunction with GALNS. As mentioned previously, β-
galactosidase activity in fibroblasts or plasma can also be used
to rule out ML II/III (not necessary if leukocytes were used),
allowing for the exclusion of two diseases with one
measurement. Additional examples of enzymes that can be
used to exclude more than one condition, including some
additional alternative MPS disorders, when testing for MPS
IVA are shown in Table 3.
Care should be taken when interpreting enzyme activity
results. Reference ranges vary significantly depending on
the units, sample type, and methodology used, as well as
among laboratories (Table 4). Laboratories should clearly
indicate reference ranges along with patient results and
provide an interpretation in this context.
Molecular analysis
Molecular analysis, also known as mutation analysis,
can be used to confirm enzyme activity results and
facilitate genetic counseling of the family. The goal is
to identify genetic mutations that result in decreased or
absent GALNS enzyme activity. Because MPS IVA is a
recessive disease, both GALNS alleles must contain a
pathogenic mutation for a patient to be affected. In
addition to pathogenic mutations, polymorphisms have
also been reported in the GALNS gene (Tomatsu et al
2005a). When a novel mutation is identified, further
investigation may be needed to determine whether or
not it is pathogenic in nature.
The GALNS gene is located on chromosome 16q24.3
(Baker et al 1993; Masuno et al 1993), contains 14 exons
(Nakashima et al 1994), and generates a 1566 nucleotide
mRNA (Tomatsu et al 1991). A review of 148 unique muta-
tions was published in 2005 (Tomatsu et al 2005a) and the
identification of additional mutations continues at a steady
pace to date. Mutation types reported in the Human Gene
Mutation Database (HGMD) include missense, nonsense,
splicing, small insertions and deletions, gross insertions and
deletions, and complex rearrangements (Table 5). There is
limited published data regarding mutation analysis of the
GALNS gene, however the most commonmutations published
to date are reported to be missense mutations c.1156C>T
(p.Arg386Cys), c.901G>T (p.Gly301Cys), and c.337A>T
(p.Ile113Phe) (Tomatsu et al 2005a). However, their allelic
frequencies are only 8.9, 6.8, and 5.7 %, respectively, dem-
onstrating the allelic heterogeneity ofMPS IVA (Tomatsu et al
2005a). Allelic frequencies are also very population-
dependent. For example, the c.337A>T (p.Ile113Phe) muta-
tion was actually found to be much more common (identified
in 32 % of patients) in a cohort of United Kingdom/Eire
Table 3 Enzymes that can be measured in addition to GALNS to
exclude more than one alternative condition
MSD ML II/IIIa MPS
β-galactosidase ● MPS IVB
Arylsulfatase B (ASB) ● ● MPS VI
Iduronate-2-sulfatase ● ● MPS II
α-iduronidase ● MPS I
a Enzyme levels in leukocytes will not be affected by ML II/III
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patients (n=89) evaluated at the Central Manchester University
Hospitals in the United Kingdom (unpublished data).
Molecular analysis is typically performed using a blood
sample. DNA in dried blood samples is very stable (Chaisomchit
et al 2005) and, therefore, can be shipped easily. Specific col-
lection cards are available for samples intended for DNA anal-
ysis; collection card selection should be as per receiving
laboratory recommendations. It is important to note that blood
samples from patients who have undergone a recent blood
transfusion or a bone marrow/stem cell transplant at any time
may give inaccurate results as these samples will likely be
contaminated with donor DNA. These samples are not recom-
mended for genotype analysis. If the initial biochemical diagno-
sis has been performed on fibroblasts, then the same cells could
also be used as a source of patient DNA. Saliva samples and
buccal swabs are additional acceptable sources of DNA.
In standard DNA sequencing-based methods, coding
regions of the GALNS gene and small segments of immedi-
ately adjacent intronic regions are evaluated. Numerous
MPS IVA mutations are believed to be “private” and found
in only one individual or family (Tomatsu et al 2005a).
Although many mutations have been reported in the litera-
ture, novel, unreported mutations are still commonly
detected (Table 6). Unfortunately, conclusively determining
whether a novel mutation is pathogenic may not always be
possible. It is notable that some of the known pathogenic
mutations in MPS IVA result in conservative amino acid
changes, such as the common pathogenic mutation p.Ile113-
Phe, highlighting the difficulty in predicting the pathogenic
nature of a novel mutation without associating enzyme
activity testing results. Development of a global database
of mutations with associated degree of compromised en-
zyme activity and phenotypic correlations could potentially
facilitate improved dissemination of information and help
reduce the number of mutations with unknown significance
identified by GALNS sequencing.
While DNA sequencing-based methods identify mis-
sense mutations, nonsense mutations, and small insertions
and deletions in the coding region of the gene, mutations
that cause splicing alterations (Pajares et al 2012) or changes
in copy number (Fukuda et al 1996) may be missed. If a
pathogenic mutation is not found in each allele, evaluation
of cDNA may be helpful in identifying intronic mutations
causing splicing errors (Pajares et al 2012) and quantitative
methods of molecular analysis can be used to identify muta-
tions affecting copy number, such as large insertions and
deletions (Fukuda et al 1996). A variety of methods are
available including real-time PCR, comparative genomic
hybridization (CGH), and multiplex ligation-dependent
probe amplification (MLPA). Unfortunately, even when
both sequencing and quantitative methods are used, some
mutations, such as those in promoter regions, will still not
be detectable. Undetectable mutations have been reported in
the literature to occur in approximately 14 % of alleles
(Tomatsu et al 2005a).
When two pathogenic mutations are successfully identi-
fied, it is important to confirm that they are on separate
alleles (in trans) because more than one mutation may be
Table 4 Laboratory-specific reference ranges from five example laboratories. Reference ranges vary based on methods, sample type, and units
used for reporting, they also vary among laboratories even using the same method
Substrate Sample type Laboratory Units Normal range Affected range
4MU-Gal-6S fibroblasts Lab #1 nmol/h/mg protein 3.9–45.9 0–0.12
Lab #2 nmol/17 h/mg protein 12–26 0.5–1.2
Lab #3 76–255 0–10
Lab #4 40–170 <16
leukocytes Lab #1 nmol/h/mg protein 11.0–44.6 0.08–3.2
Lab #2 nmol/17 h/mg protein 87–180 2–11
Lab #3 34–347 0–10
DBS Lab #4 μmol/L/20 h >8 <4.5
GalNAc6S-glcA-[1-3H]galitolNAc6S fibroblasts Lab #5 pmol/min/mg protein 18–72 <6
leukocytes Lab #5 39–166 <2.7
Table 5 GALNS mutations as reported by the HGMD database (http://
www.hgmd.org/)
Mutation type # of unique mutations
Missense 120
Nonsense 11
Splicing 14
Small deletions 18
Small insertions 3
Small indels 1
Gross deletions 4
Gross insertions/duplications 2
Complex rearrangements 2
Accessed June 11, 2012
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present on the same allele (in cis). It is also important to
identify any in cis mutations because their presence may
impact future prenatal diagnoses. To confirm that the muta-
tions are in trans, analyzing the parental DNA is recom-
mended. If each parent has one of the mutations, they are
likely present in trans in the patient. If both of the mutations
are identified in one parent, the two identified mutations are
likely in cis in the patient. In this case, the patient is either a
carrier (not affected) or the mutation in the second allele has
not yet been identified.
One notable exception to the mutations coming from
both parents is a recently reported case of maternal unipa-
rental isodisomy (Catarzi et al 2012). This case provides
evidence for the need to perform parental testing in all cases,
even when the patient is found to be homozygous for a
known mutation. It is also possible that a change could
occur de novo in the germ cell. These considerations high-
light the importance of parental testing in being able to
provide families with accurate genetic counseling regarding
recurrence risk.
Ultimately, although molecular analysis results can
confirm a diagnosis and allow for genetic counseling
of the family, results can also be inconclusive and
complicate the diagnostic process. Discussing the limitations
of the analysis with the patient and their family prior to testing
is recommended.
Reaching a diagnosis
There are multiple paths to a diagnosis (Fig. 1). To reach an
accurate diagnosis, it is critical that laboratory results from
different assays and sample types corroborate the diagnosis.
Any discrepancies should be investigated and resolved. The
full diagnostic process involves screening followed by en-
zyme activity analysis in fibroblasts or leukocytes and con-
firmation by molecular analysis. However, all three steps are
not always required and may not provide clinically relevant
information in all cases. When clinical suspicion of MPS
IVA is especially strong or when evaluating the sibling of an
affected individual, screening may be unnecessary. In other
cases, if screening results (urine or DBS) and enzyme activ-
ity results in fibroblasts or leukocytes are both conclusively
positive, confirmation by molecular analysis is still recom-
mended but not necessarily required. In special situations,
such as in regions where it is not feasible to transport whole
blood or other tissue samples, diagnostic evaluation of en-
zyme activity in fibroblasts or leukocytes might not be
possible. In these situations DBS enzyme activity results
from two independently collected DBSs can be combined
with molecular analysis to reach a diagnosis. On the other
hand, the combination of an isolated DBS enzyme activity
result with the detection of urinary KS, while being strongly
suggestive of MPS IVA, is not considered adequate for a
definitive diagnosis as KS excretion is not specific to MPS
IVA alone; in addition to being elevated in MPS IVB there is
some evidence that KS can be elevated in other MPS dis-
orders as well as mucolipidoses (Tomatsu et al 2005b).
The accurate diagnosis of MPS IVA rests on a thorough
clinical evaluation and multiple laboratory measures. Alone,
neither clinical features, nor laboratory results are sufficient
given the clinical and laboratory challenges and complexi-
ties involved in the diagnosis of MPS IVA.
Conclusions
Variable clinical presentation and laboratory testing caveats
make MPS IVA particularly challenging to diagnose. Both
skeletal and non-skeletal symptoms should contribute to
clinical suspicion. Radiographic imaging of multiple areas
of the body is particularly important in MPS IVA. If urinary
screening is carried out, quantitative analysis should not be
performed without qualitative analysis because total urinary
GAGs are not elevated in a significant proportion of MPS
IVA patients and KS may be detectable by qualitative anal-
ysis even when total urinary GAGs are not elevated. How-
ever, KS is not always excreted in detectable quantities by
all MPS IVA patients regardless of the method used. False
negatives can occur even if quantitative and qualitative
analyses are both performed. Proceeding to enzyme activity
analysis even if urine appears normal is recommended when
Table 6 Current rate of diagnostic challenges arising from molecular analysis for MPS IVA
Laboratorya # of patients
(alleles) analyzed
Frequency of patients (alleles)
with novel mutations
Frequency of enzymatically confirmed MPS IVA patients
(alleles) lacking one or more pathogenic mutations
Adelaide laboratory 17 (34) 35 % (26 %) 0 (0)
Willink biochemical
genetics laboratory
89 (178) 45 % (34 %) 10 % (5 %)
Greenwood Genetic
Center
6 (12) 50 % (42 %) 16 % (8 %)
a Local population genetics affect the variety of mutations seen and detection rates
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there is suspicion of MPS IVA. Enzyme activity testing of
GALNS is essential in diagnosing MPS IVA; fibroblasts and
leukocytes are the recommended sample types. Sample in-
tegrity should be confirmed as part of enzyme activity
analysis and MPS IVB should be ruled out, particularly
following positive urine results, because MPS IVA and B
both cause urinary KS excretion. If GALNS activity is low,
additional conditions causing low GALNS activity, MSD
and ML II/III (if fibroblasts were used), should also be ruled
out. If a DBS is used, collection and shipping conditions are
of critical importance and cannot be understated. DBS
results should be confirmed by enzyme activity testing in
fibroblasts or leukocytes, or by molecular testing if it is not
feasible to ship whole blood or other tissue samples. Using
molecular analysis to confirm an MPS IVA diagnosis and
provide genetic counseling to the family is recommended.
When feasible, quantification-based methods of molecular
analysis should be used to find mutations that could not be
identified by sequencing-based methods. Even with currently
available technology, two pathogenic mutations may not
always be found in every case of MPS IVA. Clinicians and
laboratories should both be aware of the possible complexities
of diagnostic testing forMPS IVA and work together to ensure
that an accurate diagnosis is reached in a timely manner.
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